

Name : Mr. B HARSHAVARDHAN TID : UMR1410939

Age/Gender : 38 Years/Male Registered On : 30-Mar-2024 08:21 AM

Ref By :

:

Reg.No : BIL4102723 Reference : Arcofemi Hea

: 30-Mar-2024 04:38 PM : Arcofemi Health Care Ltd

- Medi Whe

Reported On

## DEPARTMENT OF CARDIOLOGY 2D Echo/Doppler Study

MITRAL VALVE : Normal.

AORTIC VALVE : Normal.

TRICUSPID VALVE : Normal.

PULMONARY VALVE : Normal.

RIGHT ATRIUM : Normal.

RIGHT VENTRICLE : Normal.

LEFT ATRIUM : 3.7 cms.

LEFT VENTRICLE : EDD : 5.5 cm IVS (d) : 0.8 cm LVEF : 76 %

ESD: 3.0 cm PW (d): 0.9 cm FS: 35 %

NO LV RWMA

IAS : Intact.

IVS : Intact.

AORTA : 2.4 cms.

PULMONARY ARTERY: Normal

PERICARDIUM : Normal.

IVC / SVC / CS : Normal.

PULMONARY VEINS : Normal.

INTRA - CARDIAC MASSES : No.



: Mr . B HARSHAVARDHAN Name TID : UMR1410939

Age/Gender : 38 Years/Male Registered On: 30-Mar-2024 08:21 AM

Ref By

Reg.No : BIL4102723 Reference : Arcofemi Health Care Ltd

Reported On

- Medi Whe

: 30-Mar-2024 04:38 PM

#### **DOPPLER STUDY**

: E: 0.8 m/s A: 0.5 m/s MITRAL FLOW

**AORTIC FLOW** 1.5 m/s

PULMONARY FLOW : 0.8 m/s

#### **COLOUR FLOW MAPPING**

MR NIL AR NIL TR **TRIVIAL** PR NIL


#### **IMPRESSION:**

- \* NORMAL SIZED CARDIAC CHAMBERS
- \* NO LV RWMA
- \* GOOD LV SYSTOLIC FUNCTION
- \* NO MR / NO AR
- \* TRIVIAL TR / NO PAH
- \* NO LV CLOT / NO PE / NO VEGETATION
- To correlate clinically

\*\*\* End Of Report \*\*\*

RAJESH KANCHRLA

Reg.No - 526091 Associate Cardiologist









Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male

Ref.By : ·

Req.No : BIL4102723

TID/SID : UMR1410939/ 27406661 Registered on : 30-Mar-2024 / 08:21 AM Collected on : 30-Mar-2024 / 08:28 AM

Reported on : 30-Mar-2024 / 13:02 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

#### **DEPARTMENT OF CLINICAL PATHOLOGY**

#### Complete Urine Examination (CUE), Urine

Investigation	Result	Biological Reference Intervals
Physical Examination		
Colour	Yellow	Straw to Yellow
Method:Photo detectors(instrument)		
Appearance	Clear	Clear
Method:Photo diode array sensor		
Chemical Examination		
Reaction and pH	Acidic (5.0)	4.6-8.0
Method:Indicator		
Specific gravity	1.021	1.000-1.035
Method:Refractometry		
Protein	Negative	Negative
Method:Protein Error of pH indicators		
Glucose	Negative	Negative
Method:Glucose oxidase/Peroxidase		
Blood	Negative	Negative
Method:Peroxidase		
Ketones	Negative	Negative
Method:Sodium Nitroprusside		
Bilirubin	Negative	Negative
Method:Diazonium salt		
Leucocytes	Negative	Negative
Method:Esterase reaction		
Nitrites	Negative	Negative
Method:Modified Griess reaction		
Urobilinogen	Negative	Up to 1.0 mg/dl (Negative)
Method:Diazonium salt		(ivegative)
Microscopic Examination		
Pus cells (leukocytes)	1-2	2 - 3 /hpf
Method:Flow Digital Imaging/Microscopy		
Epithelial cells	1-2	2 - 5 /hpf
Method:Flow Digital Imaging/Microscopy		
RBC (erythrocytes)	Absent	Absent
Method:Flow Digital Imaging/Microscopy		
Casts	Absent	Occasional hyaline casts may be seen
Method:Flow Digital Imaging/Microscopy		







Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male

Ref.By : -

Reg.No : BIL4102723

TID/SID : UMR1410939/ 27406661

Registered on : 30-Mar-2024 /  $08:21\,\mathrm{AM}$ 

Collected on : 30-Mar-2024 / 08:28 AM

Reported on : 30-Mar-2024 / 13:02 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

be seen

Crystals Absent Phosphate, oxalate, or urate crystals may

Method:Flow Digital Imaging/Microscopy

Others Nil Nil

Method:Flow Digital Imaging/Microscopy

#### Method: Semi Quantitative test ,For CUE

**Reference:** Godka**r** Clinical Diagnosis and Management by Laboratory Methods, First South Asia edition. Product kit literature.

#### Interpretation:

The complete urinalysis provides a number of measurements which look for abnormalities in the urine. Abnormal results from this test can be indicative of a number of conditions including kidney disease, urinary tract infecation or elevated levels of substances which the body is trying to remove through the urine. A urinalysis test can help identify potential health problems even when a person is asymptomatic. All the abnormal results are to be correlated clinically.

\* Sample processed at National Referral Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr.K Sucharita Consultant Pathologist Reg.No - TSMC/FMR/01493





TID/SID



PLEASE SCAN QR CODE TO VERIFY THE REPORT ONLINE

Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male

Ref.By : -

Reg.No : BIL4102723

Registered on: 30-Mar-2024 / 08:21 AM

:UMR1410939/ 27406659

Collected on : 30-Mar-2024 / 08:28 AM Reported on : 30-Mar-2024 / 15:34 PM

Reference : Arcofemi Health Care Ltd -

#### **DEPARTMENT OF HEMATOPATHOLOGY**

**TEST REPORT** 

#### **Blood Grouping ABO And Rh Typing, EDTA Whole Blood**

Parameter Results

Blood Grouping (ABO) O

Rh Typing (D) Positive

Method:Hemagglutination Tube Method by Forward & Reverse Grouping

Method: Hemagglutination Tube Method by Forward & Reverse Grouping

Reference: Tulip kit literature

**Interpretation:** The ABO grouping and Rh typing test determines blood type grouping (A,B, AB, O) and the Rh factor (positive or negative). A person's blood type is based on the presence or absence of certain antigens on the surface of their red blood cells and certain antibodies in the plasma. ABO antigens are poorly expresses at birth, increase gradually in strength and become fully expressed around 1 year of age.

Note: Records of previous blood grouping/Rh typing not available. Please verify before transfusion.

\* Sample processed at National Referral Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr.K Sucharita Consultant Pathologist Reg.No - TSMC/FMR/01493





: UMR1410939/ 27406659

Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male

Ref.By :

Reg.No : BIL4102723

Registered on: 30-Mar-2024 / 08:21 AM Collected on: 30-Mar-2024 / 08:28 AM Reported on: 30-Mar-2024 / 15:34 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

TID/SID

#### **DEPARTMENT OF HEMATOPATHOLOGY**

#### Erythrocyte Sedimentation Rate (ESR), Sodium Citrate Whole Blood

Investigation	Observed Value	Biological Reference Intervals
ESR 1st Hour	11	<=10 mm/hour
Method:Westergren/Vesmatic		

Method: Westergren/Vesmatic 20

**Reference:** Dacie and Lewis Practical Hematology, 12th Edition, User Manual of Vesmatic 20/20 Plus New and Henry's Clinical Diagnosis and Management by Laboratory Methods, First South Asia edition

Interpretation: Erythrocyte sedimentation rate (ESR) is a useful but nonspecific marker of underlying inflammation.

**ESR is elevated in:** Rheumatoid arthritis, chronic infection, collagen disease, polyclonal hyperglobulinemia and hyperfibrinogenemia, Temporal arteritis, septic arthritis, pelvic inflammatory disease, and appendicitis, Osteomyelitis, Neoplastic disease (Myeloma, Macroglobulinemia, Prostate cancer, Hodgkin's disease, Renal cell carcinoma), Stroke, coronary artery disease, Pregnancy (increase at the 10th to the 12th week, and returns to normal about 1 month postpartum)

**ESR is decreased in:** Polycythemia, hyperviscosity, sickle cell anemia, leukemia, low plasma protein (liver, kidney disease) and congestive heart failure.

#### Complete Blood Count (CBC), EDTA Whole Blood

Investigation	Observed Value	Biological Reference Intervals
Hemoglobin	14.9	13.0-17.0 g/dL
Method:Spectrophotometry		
PCV/HCT	42.8	40.0-50.0 vol%
Method:Calculated		
Total RBC Count	5.15	4.50-5.50 mill /cu.mm
Method:Electrical Impedance		
MCV	83.1	83.0-101.0 fL
Method:Calculated		
MCH	29.0	27.0-32.0 pg
Method:Calculated		
MCHC	34.9	31.5-34.5 g/dL
Method:Calculated		
RDW (CV)	13.0	11.6-14.0 %
Method:Calculated		
MPV	8.6	7.0-10.0 fL
Method:Calculated		
Total WBC Count	7630	4000-10000 cells/cumm
Method:Electrical Impedance		





TO VERIFY THE REPORT ONLINE

Name
Age / Gender
Ref.By

: MR.B HARSHAVARDHAN

: 38 Years / Male

ef.By

Reg.No : BIL4102723 TID/SID : UMR1410939/ 27406659 Registered on: 30-Mar-2024 / 08:21 AM

Collected on : 30-Mar-2024 / 08:28 AM

Reported on : 30-Mar-2024 / 15:34 PM

Reference : Arcofemi Health Care Ltd -**TEST REPORT** 

	TEST REPORT	
Platelet Count	2.85	1.50-4.10 lakhs/cumm
Method:Electrical Impedance		
Differential count		40.0.00.0.4
Neutrophils	54.1	40.0-80.0 %
Method:Microscopy		
Lymphocytes	37.7	20.0-40.0 %
Method:Microscopy		
Eosinophils	1.4	1.0-6.0 %
Monocytes	6.7	2.0-10.0 %
Basophils	0.1	< 1.0-2.0 %
Method:Flowcytometry/Microscopy		
Absolute Neutrophil Count Method:Calculated	4127.83	2000-7000 cells/cumm
Absolute Lymphocyte Count (ALC)	2876.51	1000-3000 cells/cumm
Absolute Eosinophil Count (AEC)	106.82	20-500 cells/cumm
Absolute Monocyte Count Method:Calculated	511.21	200-1000 cells/cumm
Absolute Basophil Count Method:Calculated	7.63	20-100 cells/cumm
Neutrophil - Lymphocyte Ratio(NLR) Method:Calculated	1.44	0.78-3.53
RBC	Normocytic Normochro	omic
WBC	Normal in Morphology	& Distribution
Platelets	Adequate	

Method: Automated Hematology Analyzer, Microscopy

Method:Microscopy

Reference: Dacie and Lewis Practical Hematology, 12th Edition

Interpretation: A Complete Blood Picture (CBP) is a screening test which can aid in the diagnosis of a variety of conditions and diseases such as anemia, leukemia, bleeding disorders and infections. This test is also useful in monitoring a person's reaction to treatment when a condition which affects blood cells has been diagnosed. All the abnormal results are to be correlated clinically.

Note: These results are generated by a fully automated hematology analyzer and the differential count is computed from a total of several thousands of cells. Therefore the differential count appears in decimalised numbers and may not add upto exactly 100. It may fall between 99 and 101.

<sup>\*</sup> Sample processed at National Referral Laboratory, Tenet Diagnostics, Hyderabad





: UMR1410939/

Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male Registered on : 30-Mar-2024 / 08:21 AM

Ref.By : -

Req.No : BIL4102723 Reported on :

TEST REPORT Reference : Arcofemi Health Care Ltd -

Collected on :

TID/SID

Sucharita

Dr.K Sucharita Consultant Pathologist Reg.No - TSMC/FMR/01493





Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male

Ref.By : -

Reg.No : BIL4102723

TID/SID : UMR1410939/ 27406660 Registered on : 30-Mar-2024 / 08:21 AM

Collected on : 30-Mar-2024 / 08:28 AM

Reported on : 30-Mar-2024 / 19:07 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

# DEPARTMENT OF CLINICAL CHEMISTRY I Blood Urea Nitrogen (BUN), Serum Observed Value Biological Reference Interval 9.91 6-20 mg/dL

Method:Calculated

Blood Urea Nitrogen.

Investigation

Urea. 21.2 12.8-42.8 mg/dL

Method:Urease/UV

**Interpretation:** Urea is a waste product formed in the liver when protein is metabolized. Urea is released by the liver into the blood and is carried to the kidneys, where it is filtered out of the blood and released into the urine. Since this is a continuous process, there is usually a small but stable amount of urea nitrogen in the blood. However, when the kidneys cannot filter wastes out of the blood due to disease or damage, then the level of urea in the blood will rise. The blood urea nitrogen (BUN) evaluates kidney function in a wide range of circumstances, to diagnose kidney disease, and to monitor people with acute or chronic kidney dysfunction or failure. It also may be used to evaluate a person's general health status as well.

Reference: Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics

#### Creatinine, Serum

Investigation	Observed Value	Biological Reference Interval	
Creatinine.	1.06	0.70-1.20 mg/dL	
Method:Alkaline Picrate			

Interpretation: Creatinine is a nitrogenous waste product produced by muscles from creatinine. Creatinine is majorly filtered from the blood by the kidneys and released into the urine, so serum creatinine levels are usually a good indicator of kidney function. Serum creatinine is more specific and more sensitive indicator of renal function as compared to BUN because it is produced from muscle at a constant rate and its level in blood is not affected by protein catabolism or other exogenous products. It is also not reabsorbed and very little is secreted by tubules making it a reliable marker. Serum creatinine levels are increased in pre renal, renal and post renal azotemia, active acromegaly and gigantism. Decreased serum creatinine levels are seen in pregnancy and increasing age.

#### **Bun/Creatinine Ratio, Serum**

Investigation	Observed Value		
BUN/Creatinine Ratio Method:Calculated	9.35	10-20	
Note	Kindly correlate	clinically	

#### Reference:

A Manual of Laboratory Diagnostic Tests. Edition 7, Lippincott Williams and Wilkins, By Frances Talaska Fischbach, RN, BSN, MSN, and Marshall Barnett Dunning 111, BS, MS, Ph.D.





Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male

Ref.By : -

Reg.No : BIL4102723

TID/SID : UMR1410939/

Registered on: 30-Mar-2024 / 08:21 AM

Collected on :

Reported on :

Reference : Arcofemi Health Care Ltd -

\* Sample processed at National Referral Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

**TEST REPORT** 

Dr Afreen Anwar Consultant Biochemist







Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male

Ref.By : -

Req.No : BIL4102723

TID/SID : UMR1410939/ 27406662F Registered on : 30-Mar-2024 / 08:21 AM

Collected on : 30-Mar-2024 / 08:28 AM

Reported on : 30-Mar-2024 / 14:03 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

#### **DEPARTMENT OF CLINICAL CHEMISTRY I**

#### Glucose Fasting (FBS). Sodium Fluoride Plasma

Gradous rading (1 20), obtaining radina		
Investigation	Observed Value	Biological Reference Interval
Glucose Fasting Method:Hexokinase	135	Normal: <100 mg/dL Impaired FG: 100-125 mg/dL Diabetes mellitus: >/=126 mg/dL
Note	Kindly correlate clinica	ıllv

**Interpretation:** It measures the Glucose levels in the blood with a prior fasting of 9-12 hours. The test helps screen a symptomatic/ asymptomatic person who is at risk for Diabetes. It is also used for regular monitoring of glucose levels in people with Diabetes.

Reference: American Diabetes Association. Standards of Medical Care in Diabetes-2020.

\* Sample processed at National Referral Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr. Abdur Rehman Asif Consultant Biochemist Reg. No - APMC/FMR/78102









Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male

Ref.By : -

Req.No : BIL4102723

TID/SID : UMR1410939/ 27406662P Registered on : 30-Mar-2024 / 08:21 AM

Collected on : 30-Mar-2024 / 10:32 AM

Reported on : 30-Mar-2024 / 14:03 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

#### **DEPARTMENT OF CLINICAL CHEMISTRY I**

#### Glucose Post Prandial (PPBS), Sodium Fluoride Plasma

Investigation	Observed Value	Biological Reference Interval
Glucose Post Prandial Method:Hexokinase	212	Normal: <140 mg/dL Impaired PG: 140-199 mg/dL Diabetes mellitus: >/=200 mg/dL
Note	Kindly correlate clinically	

**Interpretation:** This test measures the blood sugar levels 2 hours after a normal meal. Abnormally high blood sugars 2 hours after a meal reflect that the body is not producing sufficient insulin which is indicative of Diabetes.

Reference: American Diabetes Association. Standards of Medical Care in Diabetes-2020.

\* Sample processed at National Referral Laboratory, Tenet Diagnostics, Hyderabad

--- End Of Report ---

Dr. Abdur Rehman Asif Consultant Biochemist Reg. No - APMC/FMR/78102









Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male

Ref.By : -

Reg.No : BIL4102723

Registered on: 30-Mar-2024 / 08:21 AM

:UMR1410939/ 27406659

Collected on : 30-Mar-2024 / 08:28 AM

Reported on : 30-Mar-2024 / 14:03 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

TID/SID

#### **DEPARTMENT OF CLINICAL CHEMISTRY I**

#### Glycosylated Hemoglobin (HbA1C), EDTA Whole Blood

, ,	• • • • • • • • • • • • • • • • • • • •	
Investigation	Observed Value	Biological Reference Interval
Glycosylated Hemoglobin (HbA1c) Method:High-Performance Liquid Chromatography	7.1	Non-diabetic: <= 5.6 % Pre-diabetic: 5.7 - 6.4 % Diabetic: >= 6.5 %
Estimated Average Glucose (eAG)  Method:Calculated	157	mg/dL
Note	Kindly correlate clinically	

**Interpretation**: It is an index of long-term blood glucose concentrations and a measure of the risk for developing microvascular complications in patients with diabetes. Absolute risks of retinopathy and nephropathy are directly proportional to the mean HbA1c concentration. In persons without diabetes, HbA1c is directly related to risk of

In known diabetic patients, HbA1c can be considered as a tool for monitoring the glycemic control.

Excellent Control - 6 to 7 %.

cardiovascular disease.

Fair to Good Control - 7 to 8 %,

Unsatisfactory Control - 8 to 10 %

and Poor Control - More than 10 %.

Reference: American Diabetes Association. Standards of Medical Care in Diabetes-2018.

\* Sample processed at National Referral Laboratory,

Tenet Diagnostics. Hyderabad

--- End Of Report ---

Dr. Abdur Rehman Asif Consultant Biochemist Reg. No - APMC/FMR/78102





Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male

Ref.By : -

Reg.No : BIL4102723

Registered on : 30-Mar-2024 / 08:21 AM Collected on : 30-Mar-2024 / 08:28 AM

:UMR1410939/ 27406660

Reported on : 30-Mar-2024 / 19:07 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

TID/SID

#### **DEPARTMENT OF CLINICAL CHEMISTRY I**

#### Lipid Profile, Serum

Lipia i rome, ocium		
Investigation	Observed Value	Biological Reference Interval
Total Cholesterol Method:Cholesterol Oxidase	142	Desirable: <200 mg/dL Borderline: 200-239 mg/dL High: >/=240 mg/dL
HDL Cholesterol Method:Direct Measurement	35	Low: <40 mg/dL High: >/=60 mg/dL
VLDL Cholesterol Method:Calculated	31.8	6.0-38.0 mg/dL
LDL Cholesterol Method:Calculated	75.2	Optimum: <100 mg/dL Near/above optimum: 100-129 mg/dL Borderline: 130-159 mg/dL High: 160-189 mg/dL Very high: >/=190 mg/dL
Triglycerides  Method:Enzymatic end point	159	Normal:<150 mg/dL Borderline: 150-199 mg/dL High: 200-499 mg/dL Very high: >/=500 mg/dL
Chol/HDL Ratio Method:Calculated	4.06	Low Risk: 3.3-4.4 Average Risk: 4.5-7.1 Moderate Risk: 7.2-11.0
LDL Cholesterol/HDL Ratio Method:Calculated	2.15	Desirable: 0.5-3.0 Borderline Risk: 3.0-6.0 High Risk: >6.0

Interpretation: Lipids are fats and fat-like substances which are important constituents of cells and are rich sources of energy. A lipid profile typically includes total cholesterol, high density lipoproteins (HDL), low density lipoprotein (LDL), chylomicrons, triglycerides, very low density lipoproteins (VLDL), Cholesterol/HDL ratio .The lipid profile is used to assess the risk of developing a heart disease and to monitor its treatment. The results of the lipid profile are evaluated along with other known risk factors associated with heart disease to plan and monitor treatment. Treatment options require clinical correlation.**Reference:** Third Report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 2001.

<sup>\*</sup> Sample processed at National Referral Laboratory, Tenet Diagnostics, Hyderabad





TO VERIFY THE REPORT ONLINE

Name : MR.B HARSHAVARDHAN

: 38 Years / Male Age / Gender

Ref.By

: BIL4102723 Req.No

TID/SID :UMR1410939/ 27406660 Registered on: 30-Mar-2024 / 08:21 AM Collected on : 30-Mar-2024 / 08:28 AM

Reported on : 30-Mar-2024 / 19:07 PM

Reference : Arcofemi Health Care Ltd -**TEST REPORT** 

#### **DEPARTMENT OF CLINICAL CHEMISTRY I**

#### Liver Function Test (LFT), Serum

Investigation	Observed Value	Biological Reference Interval
Total Bilirubin. Method:Diazo method	0.63	<1.2 mg/dL
Direct Bilirubin. Method:Diazo method	0.29	<0.30 mg/dL
Indirect Bilirubin.  Method:Calculated	0.34	<0.9 mg/dL
Alanine Aminotransferase ,(ALT/SGPT)  Method: IFCC without pyridoxal phosphate activation	20	<45 U/L
Aspartate Aminotransferase,(AST/SGOT)  Method: IFCC without pyridoxal phosphate activation	14	<35 U/L
ALP (Alkaline Phosphatase).  Method:PNPP-AMP Buffer	73	40-129 U/L
Gamma GT.  Method:Gamma-Glutamyl - 3 - Carbossi - 4 - Nitroanilide (GCNA)	47	10-71 U/L
Total Protein.  Method:Biuret	7.3	6.6-8.7 g/dL
Albumin. Method:Bromocresol Green (BCG)	4.7	3.5-5.2 g/dL
Globulin. Method:Calculated	2.60	1.8-3.8 g/dL
A/GRatio.  Method:Calculated	1.81	0.8-2.0

Interpretation: Liver functions tests help to identify liver disease, its severity, and its type. Generally these tests are performed in combination, are abnormal in liver disease, and the pattern of abnormality is indicative of the nature of liver disease. An isolated abnormality of a single liver function test usually means a non-hepatic cause. If several liver function tests are simultaneously abnormal, then hepatic etiology is likely.

Tenet Diagnostics, Hyderabad



<sup>\*</sup> Sample processed at National Referral Laboratory,







Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male

Ref.By :

Req.No : BIL4102723

TID/SID : UMR1410939/ 27406660 Registered on : 30-Mar-2024 / 08:21 AM

Collected on : 30-Mar-2024 / 08:28 AM Reported on : 30-Mar-2024 / 19:07 PM

Reference : Arcofemi Health Care Ltd -

#### **DEPARTMENT OF CLINICAL CHEMISTRY I**

**TEST REPORT** 

#### Prostate Specific Antigen (PSA) Total, Serum

<b>9</b> (* 5 · 7 · 5 · 6 · 6 · 7 · 5 · 6 · 6 · 7 · 5 · 6 · 6 · 6 · 6 · 6 · 6 · 6 · 6 · 6						
Investigation	Observed Value	Biological Reference Interval				
Prostate Specific Antigen (PSA). Total Method:ECLIA	0.526	<4.4 ng/mL  Note: Biological Reference Ranges are changed due to change in method of testing.				

**Interpretation:** PSA is a protein produced by cells in the prostate and is used to screen men for prostate cancer. PSA levels are elevated in Prostate cancer, and other conditions such as benign prostatic hyperplasia (BPH) and inflammation of the prostate. An elevated PSA may be followed by a biopsy and other tests like urinalysis and ultrasound to rule out urinary tract infections and for an accurate diagnosis. PSA levels are vital to determine the effectiveness of treatment and to detect recurrence in diagnosed cases of prostate cancer.

\* Sample processed at National Referral Laboratory, Tenet Diagnostics, Hyderabad









Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male

Ref.By : -

Req.No : BIL4102723

TID/SID : UMR1410939/ 27406660 Registered on : 30-Mar-2024 / 08:21 AM Collected on : 30-Mar-2024 / 08:28 AM

Reported on : 30-Mar-2024 / 19:07 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

#### **DEPARTMENT OF CLINICAL CHEMISTRY I**

#### Thyroid Profile (T3,T4,TSH), Serum

Investigation	Observed Value	Biological Reference Interval		
Triiodothyronine Total (T3) Method:ECLIA	1.31	0.80-2.00 ng/mL  Note: Biological Reference Ranges are changed due to change in method of testing.		
Thyroxine Total (T4) Method:ECLIA	7.7	5.1-14.1 μg/dL <b>Note:</b> Biological Reference Ranges are changed due to change in method of testing.		
Thyroid Stimulating Hormone (TSH)  Method:ECLIA	2.4	0.27-4.20 µIU/mL  Note: Biological Reference Ranges are changed due to revision of reference source.		

Interpretation: A thyroid profile is used to evaluate thyroid function and/or help diagnose hypothyroidism and hyperthyroidism due to various thyroid disorders. T4 and T3 are hormones produced by the thyroid gland. They help control the rate at which the body uses energy, and are regulated by a feedback system. TSH from the pituitary gland stimulates the production and release of T4 (primarily) and T3 by the thyroid. Most of the T4 and T3 circulate in the blood bound to protein. A small percentage is free (not bound) and is the biologically active form of the hormones.

Reference: Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, Carl A. Burtis, David E. Bruns.

\* Sample processed at National Referral Laboratory, Tenet Diagnostics, Hyderabad









Name : MR.B HARSHAVARDHAN

Age / Gender : 38 Years / Male

Ref.By : -

Req.No : BIL4102723

Registered on: 30-Mar-2024 / 08:21 AM Collected on: 30-Mar-2024 / 08:28 AM

:UMR1410939/ 27406660

Reported on : 30-Mar-2024 / 19:07 PM

TEST REPORT Reference : Arcofemi Health Care Ltd -

TID/SID

# Uric Acid, Serum Investigation Uric Acid. 8.5 Method:Uricase Note DEPARTMENT OF CLINICAL CHEMISTRY I Uric Acid, Serum Biological Reference Interval 3.4-7.0 mg/dL Kindly correlate clinically

**Interpretation:** It is the major product of purine catabolism. Hyperuricemia can result due to increased formation or decreased excretion of uric acid which can be due to several causes like metabolic disorders, psoriasis, tissue hypoxia, pre-eclampsia, alcohol, lead poisoning, acute or chronic kidney disease, etc. Hypouricemia may be seen in severe hepato cellular disease and defective renal tubular reabsorption of uric acid.

\* Sample processed at National Referral Laboratory, Tenet Diagnostics, Hyderabad





#### TENET MEDCORP PVT LTD

#### GROUND FLOOR, Q-MART BUILDING, SRESHTA MARVEL, GACHIBOWLI, HYD

Patient: B HARSHAVARDHAN

: 38 Yrs

: 4102723

Gender

: Male

Refd.By:

Pred.Eqns: RECORDERS

Height: 180 Cms Weight: 92 Kgs


Age


Smoker


Temp


: No

Eth. Corr: 100









FVC Results

Parameter         Pred         M.Pre         %Pred         M.Post         %Pred         %Imp           FVC         (L)         03.98         04.09         103              FEV1         (L)         03.27         03.37         103	FVC RESULTS										
FEV1       (L)       03.27       03.37       103           FEV1/FVC       (%)       82.16       82.40       100           FEF25-75       (L/s)       04.22       04.35       103           PEFR       (L/s)       09.63       05.51       057	Parameter	•	Pred	M.Pre	%Pred	M.Post	%Pred	%Imp			
FEV1/FVC       (%)       82.16       82.40       100	FVC	(L)	03.98	04.09	103						
FEF25-75 (L/s)       04.22       04.35       103	FEV1	(L)	03.27	03.37	103						
PEFR       (L/s)       09.63       05.51       057	FEV1/FVC	(ક)	82.16	82.40	100						
FIVC (L) 03.95 FEV.5 (L) 03.86 04.09 106 FEF75-85 (L/s) 01.87 FEF 25% (L/s) 07.54 04.62 061 FEF 25% (L/s) 08.27 05.04 061 FEF 50% (L/s) 05.94 04.88 082 FEF 75% (L/s) 02.94 02.71 092 FEV.5/FVC (%) 38.39 FEV3/FVC (%) 96.98 100.00 103 FEF (Sec) 01.97 FEP 11me (Sec) 00.06 FEV6 (L) 03.98 FIF25% (L/s) 03.44 FIF50% (L/s) 03.21 FIF50% (L/s) 03.21 FIF50% (L/s) 03.21	FEF25-75	(L/s)	04.22	04.35	103						
FEV.5 (L) 01.57 FEV3 (L) 03.86 04.09 106 FEF75-85 (L/s) 01.87 FEF.2-1.2(L/s) 07.54 04.62 061 FEF 25% (L/s) 08.27 05.04 061 FEF 50% (L/s) 05.94 04.88 082 FEF 75% (L/s) 02.94 02.71 092 FEV.5/FVC (%) 38.39 FEV3/FVC (%) 96.98 100.00 103 FET (Sec) 01.97 FEP 17ime (Sec) 01.97 FEV3/FVC (L) 03.98 FEV6 (L) 03.98 FIF25% (L/s) 03.21 FIF50% (L/s) 03.21 FIF50% (L/s) 03.21	PEFR	(L/s)	09.63	05.51	057						
FEV3       (L)       03.86       04.09       106            PIFR       (L/s)        03.62            FEF75-85       (L/s)       07.54       04.62       061           FEF 25%       (L/s)       08.27       05.04       061	FIVC	(L)		03.95							
PIFR       (L/s)        03.62	FEV.5	(L)		01.57							
FEF75-85 (L/s) 01.87 FEF.2-1.2(L/s) 07.54 04.62 061 FEF 25% (L/s) 08.27 05.04 061 FEF 50% (L/s) 05.94 04.88 082 FEF 75% (L/s) 02.94 02.71 092 FEV.5/FVC (%) 38.39 FEV3/FVC (%) 96.98 100.00 103 FET (Sec) 01.97 FET (Sec) 00.06 ExplTime (Sec) 00.06 FEV6 (L) 03.98 FIF25% (L/s) 03.44 FIF50% (L/s) 03.21	FEV3	(L)	03.86	04.09	106						
FEF.2-1.2(L/s) 07.54 04.62 061 FEF 25% (L/s) 08.27 05.04 061 FEF 50% (L/s) 05.94 04.88 082 FEF 75% (L/s) 02.94 02.71 092 FEV.5/FVC (%) 38.39 FEV3/FVC (%) 96.98 100.00 103 FET (Sec) 01.97 FET (Sec) 00.06 ExplTime (Sec) 00.06 FEV6 (L) 03.98 037 097 FIF25% (L/s) 03.44 FIF50% (L/s) 03.21	PIFR	(L/s)		03.62							
FEF 25% (L/s) 08.27 05.04 061 FEF 50% (L/s) 05.94 04.88 082 FEF 75% (L/s) 02.94 02.71 092 FEV.5/FVC (%) 38.39 FEV3/FVC (%) 96.98 100.00 103 FET (Sec) 01.97 ExplTime (Sec) 00.06 Lung Age (Yrs) 038 037 097 FEV6 (L) 03.98 FIF25% (L/s) 03.44 FIF50% (L/s) 03.21	FEF75-85	(L/s)		01.87							
FEF 50% (L/s) 05.94 04.88 082 FEF 75% (L/s) 02.94 02.71 092 FEV.5/FVC (%) 38.39 FEV3/FVC (%) 96.98 100.00 103 FET (Sec) 01.97 ExplTime (Sec) 00.06 Lung Age (Yrs) 038 037 097 FEV6 (L) 03.98 FIF25% (L/s) 03.44 FIF50% (L/s) 03.21	FEF.2-1.2	(L/s)	07.54	04.62	061						
FEF 75% (L/s) 02.94 02.71 092 FEV.5/FVC (%) 38.39 FEV3/FVC (%) 96.98 100.00 103 FET (Sec) 01.97 ExplTime (Sec) 00.06 Lung Age (Yrs) 038 037 097 FEV6 (L) 03.98 FIF25% (L/s) 03.44 FIF50% (L/s) 03.21	FEF 25%	(L/s)	08.27	05.04	061						
FEV.5/FVC       (%)        38.39            FEV3/FVC       (%)       96.98       100.00       103           FET       (Sec)        01.97           ExplTime       (Sec)        00.06	FEF 50%	(L/s)	05.94	04.88	082						
FEV3/FVC       (%)       96.98       100.00       103            FET       (Sec)        01.97            ExplTime       (Sec)        00.06            Lung Age       (Yrs)       038       037       097           FEV6       (L)       03.98             FIF25%       (L/s)        03.21	FEF 75%	(L/s)	02.94	02.71	092						
FET (Sec) 01.97 ExplTime (Sec) 00.06 Lung Age (Yrs) 038 037 097 FEV6 (L) 03.98 FIF25% (L/s) 03.44 FIF50% (L/s) 03.21	FEV.5/FVC	(%)		38.39							
ExplTime (Sec) 00.06 Lung Age (Yrs) 038 037 097 FEV6 (L) 03.98 FIF25% (L/s) 03.44 FIF50% (L/s) 03.21	FEV3/FVC	(%)	96.98	100.00	103						
Lung Age (Yrs) 038 037 097 FEV6 (L) 03.98 FIF25% (L/s) 03.44 FIF50% (L/s) 03.21	FET	(Sec)		01.97							
FEV6 (L) 03.98 FIF25% (L/s) 03.44 FIF50% (L/s) 03.21	ExplTime	(Sec)		00.06							
FIF25% (L/s) 03.44 FIF50% (L/s) 03.21	Lung Age	(Yrs)	038	037	097						
FIF50% (L/s) 03.21	FEV6	(L)	03.98								
	FIF25%	(L/s)		03.44							
FIE75est (OPB) Severity 03.37	FIF50%	(L/s)		03.21							
	<b>FIE</b> 7 <b>5</b> &st	<b>(₫₫₽₽)</b> S	everity	03.37							

Test within normal limits

Pre Medication Report Indicates Early Small Airway Obstruction as FEF 25-75 %Pred or PEFR %Pred < 70 Spirometry within normal limits as (FEV1/FVC)%Pred >95 and FVC%Pred >80



Name : Mr. B HARSHAVARDHAN TID : UMR1410939

Age/Gender : 38 Years/Male Registered On : 30-Mar-2024 08:21 AM

Ref By : Reported On : 30-Mar-2024 02:03 PM

Reg.No : BIL4102723 Reference : Arcofemi Health Care Ltd - Medi Whe

### DEPARTMENT OF ULTRASOUND **Ultrasound Whole Abdomen**

**CLINICAL DETAILS**: Health checkup.

**LIVER:** Mildly enlarged in size (16.0 cms) with increased echopattern. No evidence of focal lesion. No intrahepatic biliary ductal dilatation. Hepatic and portal vein radicals are normal.

**GALL BLADDER** shows normal shape and has clear contents. Gall bladder wall is of normal thickness.

CBD is of normal calibre.

**PANCREAS** has normal shape, size and uniform echopattern.

No evidence of ductal dilatation or calcification.

**SPLEEN:** Borderline enlarged in size (12.5 cms) and echopattern.

**KIDNEYS** move well with respiration and have normal shape, size and echopattern. Cortico-medullary differentiations are well madeout.

No evidence of calculus or hydronephrosis.

Right kidney measures: 11.6 x 4.5 cms, Left kidney measures: 11.0 x 6.0 cms.

**URINARY BLADDER** shows normal shape and wall thickness.

It has clear contents. No evidence of diverticula.

**PROSTATE** shows normal shape, size and echopattern.

It measures: 3.1 x 3.2 x 3.2 cms, Vol: 17 cc.

No evidence of free fluid in the abdomen and pelvis.



Name : Mr. B HARSHAVARDHAN TID : UMR1410939

Age/Gender : 38 Years/Male Registered On : 30-Mar-2024 08:21 AM

Ref By :

Reported On

Reg.No : BIL4102723 Reference : Arcofemi Health Care Ltd

- Medi Whe

: 30-Mar-2024 02:03 PM

#### **IMPRESSION:**

\* MILD HEPATOMEGALY WITH GRADE I FATTY LIVER.

\* BORDERLINE SPLENOMEGALY.

- Suggested clinical correlation and follow up.

\*\*\* End Of Report \*\*\*

Dr.Sahithi Puttagunta

Consultant Radiologist Fellowship in MSK Imaging



: Mr . B HARSHAVARDHAN Name TID : UMR1410939

Age/Gender : 38 Years/Male Registered On: 30-Mar-2024 08:21 AM

Ref By

: 30-Mar-2024 12:35 PM Reported On Reg.No : BIL4102723 Reference : Arcofemi Health Care Ltd

- Medi Whe

#### **DEPARTMENT OF X-RAY** X-Ray Chest PA View

#### Clinical History: Health check up

Lung fields appear normal.

Cardiac size is within normal limits.

Aorta and pulmonary vasculature is normal.

Bilateral domes of diaphragm and costophrenic angles are normal.

Visualised bones and soft tissues appear normal.


#### **IMPRESSION:**

\* Normal study.

Suggested clinical correlation and follow up.

\*\*\* End Of Report \*\*\*

Dr.Sahithi Puttagunta Consultant Radiologist Fellowship in MSK Imaging



TENET DIAGNOSTICS GACHIBOWLI HYD